Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~1. Patients with established congenital, cyclic or idiopathic severe chronic neutropenia having an indication for treatment with Sandoz' filgrastim according to the SmPC of the product~2. Patients ≥ 18 years of age at the day of inclusion~3. Written informed consent of patient~Exclusion criteria:.~1. Chemotherapy-induced neutropenia~2. Neutropenia in combination with confirmed diagnosis of autoimmune disease, e.g. rheumatoid arthritis, Felty's syndrome, or systemic lupus erythematosus~3. Myelodysplastic syndrome or leukemia~4. Thrombocytopenia (platelets \< 50.000/mm3) or anemia (hemoglobin \< 8 g/dl) with the exception of patients with Shwachman-Diamond syndrome, glycogen storage disease 1b, or Barth's syndrome~5. Sickle cell disease~6. History of malignancy of any organ system, treated or untreated, with the exception of localized basal cell carcinoma of the skin~7. For patients with congenital severe chronic neutropenia only: Any cytogenetic aberrations in bone marrow aspirates with results not older than six months suspicious for malignant transformation.~8. Known or suspected hypersensitivity to rhG-CSF products~9. Known or suspected hypersensitivity to any of the excipients of Sandoz' filgrastim product~10. Positive result of anti-rhG-CSF antibody assessment at screening~11. Absolute and relative contraindications as specified in the SmPC of Sandoz' filgrastim~12. Drug abuse, substance abuse, or alcohol abuse~13. Use of any other investigational drug at the time of enrollment, or within 30 days or 5 half-lives prior to enrollment, whichever is longer~14. Patients unwilling and/or who are not capable of ensuring compliance with the provisions of the study protocol~15. Pregnant or breastfeeding women where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive serum hCG laboratory test~16. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, UNLESS they are using a highly effective method of birth control (i.e. one that results in a less than 1% per year failure rate when used consistently and correctly, such as implants, injectables, combined oral contraceptives and intrauterine devices (IUDs)). Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) is not acceptable.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zarzio®/Filgrastim HEXAL® (Type: EXPERIMENTAL): Zarzio®/Filgrastim HEXAL® was administered according to Summary of Product Characteristics (SmPC). It was provided as solution for injection in prefilled syringes with two strengths at 300 μg/0.5 ml (30 MU) and 480 μg/0.5 ml (48 MU).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy